Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on uniQure (QURE) to $58 from $28 and keeps an Overweight rating on the shares. uniQure announced alignment with the FDA towards an accelerated approval path for AMT-130 in Huntington’s disease, with the FDA agreeing that data from the current study could serve as the basis for a biologics license application for accelerated approval, Cantor Fitzgerald analyst Kristen Kluska tells investors in a research note. The firm believes uniQure could see significant pharma interest now that there is a potential green light for the path forward.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure trading halted, volatility trading pause
- Stifel says FDA alignment on accelerated path ‘looks like best case’ for uniQure
- Cantor Fitzgerald says ‘aggressively’ buy uniQure, PTC Therapeutics
- uniQure Secures FDA Agreement for AMT-130 Approval
- uniQure announces alignment with FDA on elements of approval path for AMT-130